SUNNYVALE, Calif., Jan. 17, 2016 (GLOBE NEWSWIRE) -- Silicon Valley Eye Physicians is proud to announce that they have acquired the revolutionary LipiFlow device to treat patients suffering with dry eye due to Meibomian Gland Dysfunction (MGD). Presently, the LipiFlow is the most innovative device available for treating MGD. The Meibomian glands are located in the eyelids: They are responsible for producing a protective layer of tear film. If these glands become blocked, the individual's tears evaporate quickly; thus, causing discomfort, irritation and, if left untreated, gland dropout.
When the structure and/or function of the Meibomian glands become compromised, MGD results. Diagnosing a patient with MGD requires a series of evaluations: One of which may be conducted using the LipiView interferometer. The LipiView interferometer is unique in that it is the only device of its kind. LipiView enables eye doctors to take images of the Meibomian glands and the tear film, allowing for an accurate evaluation of the Meibomian glands. The LipiView interferometer allows eye doctors to capture images to determine the thickness of the lipid component.
LipiFlow makes it possible for the physicians at Silicon Valley Eye Physicians to address gland blockages, which are the root cause of MGD. Although there are numerous options available for treating MGD, the only FDA-approved device for the removal of Meibomian gland blockages to restore function is LipiFlow. Treatment with LipiFlow involves utilizing an algorithm of heat application to the inner eyelids, in conjunction with massage, allowing for the removal of the Meibomian glands’ obstructions.
Dr. David Mark states that, “There are approximately 30 million people in the United States who are suffering with dry eye: The majority of these people find relief with temporary treatment methods, such as eye drops. Temporary relief was the only option for individuals with dry eye because until now, the root cause of dry eye was unclear; finally, after more than 25 years of research, the condition Meibomian Gland Dysfunction (MGD) was discovered. MGD is a chronic condition that progresses with time. We can now offer our patients who are diagnosed with MGD a more permanent solution with LipiFlow treatments.”
The Silicon Valley Eye Physicians’ clinics in Sunnyvale and Santa Clara are the only eye care clinics in Silicon Valley currently offering LipiFlow treatments. These clinics also offer routine eye exams (adults and children), prescription contact lenses, eyeglasses, LASIK eye surgery, screening and treatment for conditions like cataracts, glaucoma, diabetic eye disease, as well as cosmetic surgery for issues related to the eyelids. For more information visit them online at www.eyelink.com.
Silicon Valley Eye Physicians, 408-739-6200


SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 



